

<b>Indication</b>	<p>The treatment of hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in post-menopausal patients (or if pre- or peri-menopausal, patient has undergone ovarian ablation or suppression with LHRH agonist treatment).</p> <p>The patient either has:</p> <ul style="list-style-type: none"> <li>• progressive disease whilst still receiving adjuvant or neoadjuvant endocrine therapy for early breast cancer with no subsequent endocrine therapy received following disease progression.</li> <li>• progressive disease within 12 or less months of completing adjuvant endocrine therapy for early breast cancer with no subsequent endocrine therapy received following disease progression</li> <li>• progressive disease on 1st line endocrine therapy for advanced/metastatic breast cancer with no subsequent endocrine therapy received following disease progression.</li> </ul> <p>NB The patient should have had no prior treatment with a CDK 4/6 inhibitor unless either abemaciclib (in combination with fulvestrant) or palbociclib (in combination with fulvestrant) has had to be stopped within 6 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression or ribociclib has been received as part of an early access scheme for the combination of ribociclib plus fulvestrant and the patient meets all the other commissioning criteria.</p>
<b>Treatment Intent</b>	Palliative
<b>Frequency and number of cycles</b>	<p>Every 28 days</p> <p>Until disease progression or excessive toxicity or patient choice to discontinue.</p>
<b>Monitoring parameters pre-treatment</b>	<ul style="list-style-type: none"> <li>• <b>Virology screening:</b> All new patients referred for systemic anti-cancer treatment should be screened for hepatitis B and C and the result reviewed prior to the start of treatment. Patients not previously tested who are starting a new line of treatment, should also be screened for hepatitis B and C. Further virology screening will be performed following individual risk assessment and clinician discretion.</li> <li>• If patient is pre- or peri-menopausal they must have undergone ovarian ablation or suppression with LHRH agonist treatment.</li> <li>• Monitor FBC, U&amp;E and LFT at baseline then at the beginning of each cycle. On cycle 1 monitor FBC, U&amp;E and LFT on Day 15. Correct abnormalities in potassium, calcium, phosphorus and magnesium prior to initiating treatment.</li> <li>• If neuts <math>\geq 1</math> and PLT <math>\geq 100</math> proceed.</li> <li>• If PLT 50-99 and neuts <math>\geq 1</math> proceed with fulvestrant, withhold ribociclib and alert consultant.</li> <li>• If PLT <math>\geq 100</math> and neuts <math>&lt; 1</math> proceed with fulvestrant, withhold ribociclib and alert consultant.</li> <li>• If PLT <math>&lt; 50</math> and neuts <math>&lt; 1</math> delay both drugs for 1 week.</li> <li>• NB: Platelets should be <math>\geq 50</math> for intramuscular injection with fulvestrant.</li> <li>• If grade <math>\geq 2</math> hepatic abnormalities are noted (see table 2 below), more frequent monitoring is recommended. After 6 months, frequency of blood tests may be reduced at clinician discretion.</li> <li>• ECG before starting treatment and then on day ~14 of cycle 1 and before cycle 2, then as clinically indicated. In case of QTcF prolongation during treatment, more frequent ECG monitoring is recommended.</li> <li>• The use of ribociclib should be avoided in patients who already have or who are at significant risk of developing QTc prolongation including; patients with long QT syndrome, with uncontrolled or</li> </ul>

Protocol No	BRE-072	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V2	Written by	M.Archer
Supersedes version	V1	Checked by	C.Waters O.Adebayo
Date	15.5.2023	Authorising consultant (usually NOG Chair)	J.Hall

significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias, and patients with electrolyte abnormalities.

- **Dose Modifications of ribociclib:** First dose reduction to 400mg/day, second dose reduction to 200mg/day. If further dose reduction required, discontinue treatment
- **Haematological and non-haematological toxicities of ribociclib:** see tables below.
- If platelets <100 discuss dose modification of ribociclib with consultant.
- **Hepatic impairment:**
  - No dose adjustment of fulvestrant is required for patients with mild or moderate hepatic impairment (Child-Pugh classes A and B), although use fulvestrant with caution.
  - No dose adjustment of ribociclib is required in patients with mild hepatic impairment. In patients with moderate and severe hepatic impairment (Child-Pugh B&C) ribociclib dose should be reduced to 400mg/day.
- **Renal impairment:**
  - No dose adjustment of fulvestrant is required for patients with mild or moderate renal impairment (CrCl  $\geq$ 30 mL/min). Insufficient data are available in patients with severe renal impairment or those requiring haemodialysis to provide any dose adjustment recommendation, administer with caution.
  - No dose adjustment of ribociclib is required in patients with mild or moderate renal impairment. A starting dose of ribociclib 200mg/day is recommended in patients with severe renal impairment (CrCl <30 mL/min), use with caution and monitor closely for signs of toxicity.
- **Adverse drug reactions** include neutropenia, leukopenia, headache, back pain, nausea, fatigue, diarrhoea, vomiting, constipation, alopecia, abnormal liver function test, lymphopenia, hypophosphataemia.
- **Interstitial lung disease/pneumonitis**
- Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis (e.g. hypoxia, cough, dyspnoea). See table 5 below for dose modification and guidance in patients who have new or worsening respiratory symptoms and are suspected to have developed ILD/pneumonitis.
- Cases of toxic epidermal necrolysis (TEN) have been reported with ribociclib treatment. If signs and symptoms suggestive of severe cutaneous reactions (e.g. progressive widespread skin rash often with blisters or mucosal lesions) appear, ribociclib should be discontinued immediately.
- **Drug & food interactions:** Avoid concomitant use with strong CYP3A4 inhibitors (eg ketoconazole, itraconazole, clarithromycin) and consider an alternative medication with no or minimal CYP3A4 inhibition. If patients must be co-administered a strong CYP3A4 inhibitor, reduce ribociclib dose to 400mg/day (or where dose already reduced, to the next dose level). If the strong inhibitor is discontinued, the ribociclib dose should be changed to the dose used prior to the initiation of the strong CYP3A4 inhibitor after at least 5 half-lives of the strong CYP3A4 inhibitor.  
Concomitant use with medicinal products known to prolong QTc interval should be avoided as this may lead to clinically meaningful prolongation of the QTcF interval.  
Caution with CYP3A4 substrates with a narrow therapeutic index (e.g. cyclosporin, fentanyl, tacrolimus); the dose of these agents may need to be reduced as ribociclib may increase their exposure. Concomitant use of the following CYP3A4 substrates should be avoided: alfuzosin, amiodarone, cisapride, pimozone, quinidine, ergotamine, dihydroergotamine, quetiapine, lovastatin, simvastatin, sildenafil, midazolam, triazolam.  
Concomitant use of ribociclib with strong CYP3A4 inducers (carbamazepine, phenytoin, rifampicin, St John's Wort) should be avoided as it may lead to reduced ribociclib exposure.  
Contraindicated in patients with a peanut or soya allergy.

Protocol No	BRE-072	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V2	Written by	M.Archer
Supersedes version	V1	Checked by	C.Waters O.Adebayo
Date	15.5.2023	Authorising consultant (usually NOG Chair)	J.Hall

	<ul style="list-style-type: none"> <li>• <b>Driving:</b> Patients should be advised to be cautious when driving or using machines in case they experience fatigue, dizziness or vertigo.</li> <li>• For oral self-administration: refer to local Trust policy on oral anti-cancer medicines and supply Patient Information Leaflet and Macmillan information sheet</li> </ul>
<b>Reference(s)</b>	SPC accessed on line 10.05.2023 CDF list v1.169 accessed online 14.10.20

NB For funding information, refer to CDF and NICE Drugs Funding List

Protocol No	BRE-072	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V2	Written by	M.Archer
Supersedes version	V1	Checked by	C.Waters O.Adebayo
Date	15.5.2023	Authorising consultant (usually NOG Chair)	J.Hall

Table 1 Dose modification of ribociclib – Neutropenia

	<b>Grade 1 or 2</b> Neuts 1 - ≤LLN	<b>Grade 3</b> Neuts 0.5 - <1	<b>Grade 3 febrile neutropenia</b> Neuts 0.5 - <1 and single fever >38.3°C (or above 38°C for more than one hour and/or concurrent infection)	<b>Grade 4</b> Neuts < 0.5
<b>Neutropenia</b>	No dose adjustment is required	Dose interruption until recovery to grade ≤2. Resume at the same dose level. If toxicity recurs at grade 3: dose interruption until recovery to grade ≤2, then resume and reduce by 1 dose level.	Dose interruption until recovery to grade ≤2. Resume and reduce by 1 dose level	Dose interruption until recovery to grade ≤2. Resume and reduce by 1 dose level.

Table 2 Dose modification of ribociclib – Hepatobiliary toxicity

	<b>Grade 1</b> (> ULN – 3 x ULN)	<b>Grade 2</b> (>3 to 5 x ULN)	<b>Grade 3</b> (>5 to 20 x ULN)	<b>Grade 4</b> (>20 x ULN)
<b>AST and/or ALT elevations from baseline, without increase in total bilirubin above 2 x ULN</b>	No dose adjustment is required.	Baseline grade <2: Dose interruption until recovery to ≤ baseline grade, then resume at same dose level. If grade 2 recurs, resume at next lower dose level. Baseline grade = 2: No dose interruption.	Dose interruption until recovery to ≤ baseline grade, then resume at next lower dose level. If grade 3 recurs, discontinue.	Discontinue
<b>Combined elevations in AST and/or ALT together with total bilirubin increase, in the absence of cholestasis</b>	If patients develop ALT and/or AST >3 x ULN along with total bilirubin >2 x ULN irrespective of baseline grade, discontinue.			

Protocol No	BRE-072	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V2	Written by	M.Archer
Supersedes version	V1	Checked by	C.Waters O.Adebayo
Date	15.5.2023	Authorising consultant (usually NOG Chair)	J.Hall

**Table 3 Dose modification of ribociclib – QT prolongation**

<b>ECGs with QTcF &gt;480 msec</b>	<ol style="list-style-type: none"> <li>The dose should be interrupted.</li> <li>If QTcF prolongation resolves to &lt;481 msec, resume treatment at the same dose level.</li> <li>If QTcF <math>\geq</math>481 msec recurs, interrupt dose until QTcF resolves to &lt;481 msec and then resume at the next lower dose level.</li> </ol>
<b>ECGs with QTcF &gt;500 msec</b>	<p>If QTcF is greater than 500 msec, interrupt until QTcF is &lt;481 msec then resume at next lower dose level.</p> <p>If QTcF interval prolongation to greater than 500 msec or greater than 60 msec change from baseline occurs in combination with torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia, permanently discontinue.</p>

**Table 4 Dose modification of ribociclib**

<b>Other toxicities excluding thrombocytopenia</b>	<b>Grade 1 or 2</b>	<b>Grade 3</b>	<b>Grade 4</b>
	No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.	Dose interruption until recovery to grade $\leq$ 1, then resume at the same dose level. If grade 3 recurs, resume at the next lower dose level.	Discontinue

**Table 5 Dose modification of ribociclib and management – ILD/pneumonitis**

	<b>Grade 1 (asymptomatic)</b>	<b>Grade 2 (symptomatic)</b>	<b>Grade 3 or 4 (severe)</b>
<b>ILD/pneumonitis</b>	No dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.	Dose interruption until recovery to grade <1, then resume at the next lower dose level	Discontinue

Protocol No	BRE-072	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	V2	Written by	M.Archer
Supersedes version	V1	Checked by	C.Waters O.Adebayo
Date	15.5.2023	Authorising consultant (usually NOG Chair)	J.Hall

## Cycle 1: Cycle length - 28 days

Day	Drug	Dose	Route	Infusion Duration	Administration
1	<b>FULVESTRANT</b>	<b>500mg</b>	intramuscular	Each 5ml (250mg) injection over 1-2 minutes	Administered as 2 x 250mg (5ml) injections, one in each buttock.
15	<b>FULVESTRANT</b>	<b>500mg</b>	intramuscular	Each 5ml (250mg) injection over 1-2 minutes	Administered as 2 x 250mg (5ml) injections, one in each buttock.
TTO	Drug	Dose	Route	Directions	
1	<b>RIBOCICLIB</b>	<b>600mg</b>	PO	OD for 21 days followed by a 7 day break Swallow whole, do not chew, crush or split tablets prior to swallowing. Take the dose at approximately the same time each day. If a dose is missed or vomiting occurs, an additional dose should not be taken that day. Do not take with grapefruit juice / fruit. Available as 200mg tablets	
	Metoclopramide	10mg	PO	TDS PRN. Do not take for more than 5 days continuously. Dispense with cycle 1 and then only if required.	

## Cycle 2 onwards: repeat every 28 days

Day	Drug	Dose	Route	Infusion Duration	Administration
1	<b>FULVESTRANT</b>	<b>500mg</b>	intramuscular	Each 5ml (250mg) injection over 1-2 minutes	Administered as 2 x 250mg (5ml) injections, one in each buttock.
TTO	Drug	Dose	Route	Directions	
1	<b>RIBOCICLIB</b>	<b>600mg</b>	PO	od for 21 days followed by a 7 day break Swallow whole, do not chew, crush or split tablets prior to swallowing. Take the dose at approximately the same time each day. If a dose is missed or vomiting occurs, an additional dose should not be taken that day. Do not take with grapefruit juice / fruit. Available as 200mg tablets	
	Metoclopramide	10mg	PO	TDS PRN. Do not take for more than 5 days continuously. Dispense with cycle 1 and then only if required.	

Protocol No	BRE-072	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	V2	Written by	M.Archer	
Supersedes version	V1	Checked by	C.Waters O.Adebayo	
Date	15.5.2023	Authorising consultant (usually NOG Chair)	J.Hall	